Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2022-04-20 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物第四届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the fourth board of directors of Zhengzhou Antu Bioengineering Co., Ltd. It details the meeting attendance, voting results, and approval of proposals related to the use of idle raised funds and idle own funds for cash management. The document references related independent opinions and verification opinions but does not contain financial statements or detailed financial data. It is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1106 characters), and it is not a report or financial statement itself but an announcement of board decisions.
2022-04-20 Chinese
安图生物关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle raised funds for cash management. It details the amounts of idle funds from publicly issued convertible bonds and non-public stock issuance, the types of financial products to be purchased (structured deposits, large certificates of deposit), investment limits, risk control measures, and approvals from the board, supervisory committee, and sponsor institution. The document is a formal disclosure about the company's financing fund management activities, specifically the use of idle raised funds for cash management. It does not contain financial statements or quarterly/yearly financial results, nor is it a report or transcript. It is an update on the company's capital/financing activities related to the management of raised funds. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is over 5,000 characters and contains detailed information, so it is not a mere announcement of a report (RPA) or a regulatory filing (RNS).
2022-04-20 Chinese
安图生物独立董事关于公司第四届董事会第三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Zhengzhou Antu Bioengineering Co., Ltd. regarding the company's board meeting resolutions on the use of idle raised funds and idle own funds for cash management. It discusses compliance with company law, company articles, and regulatory guidelines, and approves specific financial management proposals. The document is not a full financial report, earnings release, or audit report, but rather a formal opinion related to board decisions. It is not a report publication announcement or a certification letter. The content fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on company financial management decisions.
2022-04-20 Chinese
安图生物第四届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Zhengzhou Antu Bioengineering Co., Ltd. It details the meeting date, attendance, voting results, and approval of proposals related to the use of idle raised funds and idle own funds for cash management. The document is short (1100 characters) and primarily announces the decisions made at a board meeting rather than providing detailed financial data or a full report. It references disclosures on the Shanghai Stock Exchange website but does not contain financial statements or detailed analysis itself. This fits the category of a Regulatory Filing (RNS) as it is a formal announcement of board resolutions and compliance with regulatory requirements, not a full report or financial statement.
2022-04-20 Chinese
招商证券关于安图生物使用闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of idle raised funds by Zhengzhou Antu Bioengineering Co., Ltd. for cash management. It references regulatory approvals, fundraising amounts, use of funds, investment products, risk control measures, and board approvals. The document is not a full financial report but a regulatory compliance and verification statement related to the use of raised funds. It does not contain financial statements or earnings data but is a formal regulatory disclosure about fundraising and fund usage compliance. This fits best under Regulatory Filings (RNS) as it is a compliance and verification report rather than a financial report or announcement of a report.
2022-04-20 Chinese
安图生物关于解除对全资子公司银行贷款提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the release of a bank loan guarantee provided to its wholly-owned subsidiary. It details the guarantee amount, the release of the guarantee, and confirms no overdue guarantees. The document is short (903 characters) and focuses on a specific financing-related event (release of guarantee). It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. This fits the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as guarantees and loans.
2022-04-20 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.